REVIEW ARTICLE
The impact of COVID-19 on the course and possible initiation of ulcerative colitis
1
Student Research Group at the Chair and Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
2
Department of Biomedicine and Environmental Research, Institute of Biological Sciences, The John Paul II Catholic University, Lublin, Poland
3
Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
4
Collegium Medicum Dr Władysław Biegański, Jan Długosz University, Częstochowa, Poland
These authors had equal contribution to this work
Submission date: 2025-02-20
Final revision date: 2025-09-04
Acceptance date: 2025-09-19
Online publication date: 2026-07-07
Corresponding author
Marcin Pieniak
Student Research Group at the Chair and Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland.
Student Research Group at the Chair and Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Zabrze, Poland.
KEYWORDS
TOPICS
ABSTRACT
This review presents an analysis of the available scientific research concerning the impact of COVID-19 infection on the course of ulcerative colitis (UC). There are cases suggesting that SARS-CoV-2 infection may be associated with exacerbations of UC; however, establishing a direct cause-and-effect relationship remains difficult. The exacerbations observed in UC patients during the COVID-19 pandemic may be attributable to stress-related factors. In addition, infection in UC patients may lead to complications and therapeutic challenges. The available reports indicate a potential role of COVID-19 as a triggering factor for the development of UC. Although further research is required to elucidate the role of this infection in both the progression and initiation of UC, current data suggest its potential significance in symptom exacerbation and triggering of autoimmune processes. Yet larger registry and longitudinal data suggest that COVID-19 usually does not worsen UC in the long term.
REFERENCES (41)
1.
Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet. 2012; 380: 1606-1619.
2.
Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond). 2021; 21(2): 135-139.
3.
Du L, Ha C. Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol Clin North Am. 2020; 49(4): 643-654.
4.
Sun Y, Zhang Z, Zheng CQ, Sang LX. Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: a review. World J Gastroenterol. 2021; 27(22): 2963-2978.
5.
Kaenkumchorn T, Wahbeh G. Ulcerative colitis: making the diagnosis. Gastroenterol Clin North Am. 2020; 49(4): 655-669.
7.
da Silva BC, Lyra AC, Rocha R, Santana GO. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol. 2014; 20(28): 9458-9467.
8.
Matsuoka K. Fecal microbiota transplantation for ulcerative colitis. Immunol Med. 2021; 44(1): 30-34.
9.
Adams SM, Bornemann PH. Ulcerative colitis. Am Fam Physician. 2013; 87(10): 699-705.
10.
Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, Sohail MR, Mahmood SF, Ochani R, Hussham Arshad M, Kumar A, Surani S. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and THIS. Infez Med. 2021; 29(1): 20-36.
11.
Yüce M, Filiztekin E, Özkaya KG. COVID-19 diagnosis – a review of current methods. Biosens Bioelectron. 2021; 172: 112752.
12.
Maniruzzaman M, Islam MM, Ali MH, Mukerjee N, Maitra S, Kamal MA, Ghosh A, Castrosanto MA, Alexiou A, Ashraf GM, Tagde P, Rahman MH. COVID-19 diagnostic methods in developing countries. Environ Sci Pollut Res Int. 2022; 29(34): 51384-51397.
13.
Weidinger C, Hegazy AN, Glauben R, Siegmund B. COVID-19-from mucosal immunology to IBD patients. Mucosal Immunol. 2021; 14(3): 566-573.
14.
Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF, Dahal S, Kumar H, Kv D. Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J. 2020; 96(1142): 753-758.
15.
Dvornikova KA, Bystrova EY, Churilov LP, Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep. 2021; 48(7): 5745-5758.
16.
Mounsif S, Setouani H, Nadi A, Ghalim F, Delsa H. Management of ulcerative colitis flare-ups in the era of COVID-19. Cureus. 2022; 14(12): e32153.
17.
Suda T, Takahashi M, Katayama Y, Tamano M. COVID-19 pandemic and exacerbation of ulcerative colitis. World J Clin Cases. 2021; 9(36): 11220-11227.
18.
Suda T, Takahashi M, Katayama Y, Soga K, Kobori I, Kusano Y, Tamano M. Progress of ulcerative colitis patients during the COVID-19 pandemic. World J Clin Cases. 2023; 11(23): 5462-5467.
19.
Peyrin-Biroulet L, Ylänne K, Sipes A, Segovia M, Gardiner S, Cappelleri JC, Mulvey A, Panaccione R. The Impact of the COVID-19 Pandemic on patients with ulcerative colitis: results from a global ulcerative colitis narrative patient survey. Adv Ther. 2024; 41(2): 598-617.
20.
Shen B. Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2021; 6(4): 254-255.
21.
Roy S, Sheikh SZ, Furey TS. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD. Sci Rep. 2021; 11(1): 16522.
22.
Rosen MH, Axelrad J, Hudesman D, Rubin DT, Chang S. Management of acute severe ulcerative colitis in a pregnant woman with COVID-19 infection: a case report and review of the literature. Inflamm Bowel Dis. 2020; 26(7): 971-973.
23.
Cryer B. The risks of deep vein thrombosis in patients with ulcerative colitis and COVID-19. Proc (Bayl Univ Med Cent). 2024; 37(2): 248-249.
24.
Aydın MF, Taşdemir H. Ulcerative colitis in a COVID-19 patient: a case report. Turk J Gastroenterol. 2021; 32(6): 543-547.
25.
Elbadry M, Medhat MA, Zaky S, El Kassas M. Ulcerative colitis as a possible sequela of COVID-19 infection: the endless story. Arab J Gastroenterol. 2022; 23(2): 134-137.
26.
Xia C, Dissanayake J, Badov D. A new onset of ulcerative colitis post-COVID-19: a case report. Cureus. 2023; 15(3): e36257.
27.
Swatski MD, Kaur P, Borlack RE, McBain S, Uffer J, Almad- houn O. A case series of new-onset ulcerative colitis following recent diagnosis of COVID-19. JPGN Rep. 2023; 4(4): e383.
28.
Morita A, Imagawa K, Tagawa M, Sakamoto N, Takada H. Case report: immunological characteristics of de novo ulcerative colitis in a child post COVID-19. Front Immunol. 2023; 14: 1107808.
29.
Cayley WE Jr. New-onset ulcerative colitis in patients with COVID-19. Am Fam Physician. 2022; 106(4): 362.
30.
Nawghare P, Jain S, Chandnani S, Rathi P. A case of acute severe ulcerative colitis triggered by COVID-19 infection. Cureus. 2023; 15(1): e34369.
31.
Fonseca Mora MC, Abushahin A, Gupta R, Winters H, Khan GM. Severe ulcerative colitis as a complication of mild COVID-19 infection in a vaccinated patient. Cureus. 2022; 14(6): e25783.
32.
Imperatore N, Bennato R, D’Avino A, Lombardi G, Manguso F. SARS-CoV-2 as a trigger for de novo ulcerative colitis. Inflamm Bowel Dis. 2021; 27(7): e87-e88.
33.
Kartsoli S, Vrakas S, Kalomoiris D, Manoloudaki K, Xourgias V. Ulcerative colitis after SARS-CoV-2 infection. Autops Case Rep. 2022; 12: e2021378.
34.
Shorbagi AI, Obaideen A, Jundi M. Post-COVID-19 polyautoimmunity - fact or coincidence: a case report. Front Med (Lausanne). 2023; 10: 1013125.
35.
Preziosi NA, Rizvi AH, Feerick JD, Mandelia C. De novo pediatric ulcerative colitis triggered by SARS-CoV-2 infection: a tale of 2 sisters. Inflamm Bowel Dis. 2022; 28(10): 1623-1625.
36.
Nakase H, Hayashi Y, Hirayama D, Matsumoto T, Matsuura M, Iijima H, Matsuoka K, Ohmiya N, Ishihara S, Hirai F, Abukawa D, Hisamatsu T; J-COSMOS group. Interim analysis of a multicenter registry study of COVID-19 patients with inflammatory bowel disease in Japan (J-COSMOS). J Gastroenterol. 2022; 57(3): 174-184.
37.
Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS. No durable impact of COVID-19 on intestinal disease activity in subjects with IBD. Clin Gastroenterol Hepatol. 2021; 19(11): 2312-2314.e3.
38.
Hamamoto Y, Kawamura M, Uchida H, Hiramatsu K, Katori C, Asai H, Egawa S, Yoshida K. Increased ACE2 and TMPRSS2 expression in ulcerative colitis. Pathol Res Pract. 2024; 254: 155108.
39.
Summa KC, Hanauer SB. COVID-19 and inflammatory bowel disease. Gastroenterol Clin North Am. 2023; 52(1): 103-113.
40.
Xu SW, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2023; 44(4): 695-709.
41.
Nanah R, Hamid O, Eltelbany A, Nanah MH, Nanah R, Hammad F, Khoudary G, Regueiro M. S1155 Increased pulmonary embolism and venous thrombosis in hospitalized COVID patients with inflammatory bowel disease: a national retrospective cohort study. Am J Gastroenterol. 2023; 118(10S): S884-S885.
Share
RELATED ARTICLE
| eISSN: | 2300-6722 |
| ISSN: | 1899-1874 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
